Loebel 2014.

Methods	Randomisation: randomised, no further details Blinding: double, no further details Duration: 6 weeks; 2 weeks double‐blind run in phase and 4 weeks randomised double‐blind phase Design: parallel Location: multi‐centre Setting: inpatients
Participants	Diagnosis: acute schizophrenia, no further details N = 95 Gender: 60.1% males (of initially randomised participants to lurasidone 80 mg/day) (N = 198) Age: mean 40.5 years; range 18 to 75 years for all initially randomised participants to lurasidone 80 mg/day History: no details
Interventions	Participants were firstly randomised to double‐blind treatment with lurasidone 20 mg/day, lurasidone 80 mg/day, or placebo. After 2 weeks, only participants who were randomised to lurasidone 80 mg/day (N = 198) and showed < 20% PANSS total score reduction, were re‐randomised to either: 1. dose increase: lurasidone 160 mg/day. N = 43; or 2. dose maintenance: lurasidone 80 mg/day. N = 52. Rescue medication: no details
Outcomes	Leaving the study early: due to side effects Mental state: general (PANSS total score) Global state (CGI‐Severity change) Unable to use: Weight gain (not separately presented for the two groups)
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Eligible patients were randomised to..." (pg. 476); no further details
Allocation concealment (selection bias)	Unclear risk	No details are presented
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "...to double‐blind treatment with..." (pg. 476); no further details
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "...to double‐blind treatment with..." (pg. 476); no further details
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Outcome not addressed
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Low risk	No obvious risk for other bias